Skip to content

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04442503
Enrollment
200
Registered
2020-06-22
Start date
2020-06-08
Completion date
2022-04-12
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Postpartum

Keywords

SAGE-217, Postpartum depression

Brief summary

The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.

Detailed description

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

Interventions

SAGE-217 oral capsules.

DRUGPlacebo

SAGE-217 matched-placebo oral capsules.

Sponsors

Biogen
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP. * Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT). * Participant is ≤12 months postpartum at screening and Day 1.

Exclusion criteria

* Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD. * Participant has active psychosis per investigator assessment. * Participant has a medical history of nonfebrile seizures. * Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder. * Participant has a history of sleep apnea. Note: Other protocol-defined inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Baseline and Day 15The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.

Secondary

MeasureTime frameDescription
Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) ScoreBaseline and Day 15The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis.
Percentage of Participants With HAM-D ResponseDays 15 and 45The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline.
Percentage of Participants With HAM-D RemissionDays 15 and 45The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7.
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) ResponseDay 15The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of very much improved or much improved.
Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreBaseline and Day 15The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where \<17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement.
Change From Baseline in the 17-item HAM-D Total ScoreBaseline, Days 3, 28 and 45The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis.
Change From Baseline in HAM-D SubscaleBaseline and Day 1517-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale\[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight\]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis.
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreBaseline, Days 3, 8,15, 21, 28 and 45The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement.
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreBaseline, Days 3, 8,15, 21, 28 and 45The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis.
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Up to Day 45An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total ScoreBaseline and Day 15The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement.

Countries

Spain, United Kingdom, United States

Participant flow

Recruitment details

Participants took part in study at 92 investigational sites in Spain, United Kingdom and United States from 8 June 2020 to 12 April 2022.

Participants by arm

ArmCount
Placebo
Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
98
SAGE-217 50 mg
Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.
98
Total196

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event11
Overall StudyLost to Follow-up86
Overall StudyPhysician Decision02
Overall StudyRandomized but not Treated31
Overall StudyReason not Specified01
Overall StudyWithdrawal by Subject34

Baseline characteristics

CharacteristicSAGE-217 50 mgTotalPlacebo
Age, Continuous30.0 years
STANDARD_DEVIATION 5.9
30.5 years
STANDARD_DEVIATION 5.93
31.0 years
STANDARD_DEVIATION 5.95
Ethnicity (NIH/OMB)
Hispanic or Latino
33 Participants75 Participants42 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
64 Participants120 Participants56 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants3 Participants3 Participants
Race (NIH/OMB)
Asian
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Black or African American
25 Participants43 Participants18 Participants
Race (NIH/OMB)
More than one race
3 Participants5 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants6 Participants5 Participants
Race (NIH/OMB)
White
68 Participants137 Participants69 Participants
Sex: Female, Male
Female
98 Participants196 Participants98 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 980 / 98
other
Total, other adverse events
52 / 9864 / 98
serious
Total, serious adverse events
0 / 982 / 98

Outcome results

Primary

Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15

The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.

Time frame: Baseline and Day 15

Population: Full Analysis Set(FAS)=randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM for Anxiety(HAM-A), Montgomery Åsberg Depression Rating Scale(MADRS), Clinical Global Impressions-Severity(CGI-S), Edinburgh Postnatal Depression Scale(EPDS) and Patient Health Questionnaire(PHQ-9), or at least 1 post-baseline value of CGI-I. Number analyzed=number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Baseline28.8 score on a scaleStandard Deviation 2.34
PlaceboChange From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Change from Baseline at Day 15-11.4 score on a scaleStandard Deviation 8.5
SAGE-217 50 mgChange From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Baseline28.6 score on a scaleStandard Deviation 2.49
SAGE-217 50 mgChange From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Change from Baseline at Day 15-15.6 score on a scaleStandard Deviation 7.62
Comparison: Change from Baseline at Day 15p-value: 0.000795% CI: [-6.3, -1.7]MMRM
Secondary

Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score

The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis.

Time frame: Baseline and Day 15

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) ScoreBaseline4.9 score on a scaleStandard Deviation 0.58
PlaceboChange From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) ScoreChange from Baseline at Day 15-1.6 score on a scaleStandard Deviation 1.38
SAGE-217 50 mgChange From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) ScoreBaseline5.0 score on a scaleStandard Deviation 0.66
SAGE-217 50 mgChange From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) ScoreChange from Baseline at Day 15-2.2 score on a scaleStandard Deviation 1.51
Comparison: Change from Baseline at Day 15p-value: 0.005295% CI: [-0.9, -0.2]MMRM
Secondary

Change From Baseline in HAM-D Subscale

17-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale\[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight\]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis.

Time frame: Baseline and Day 15

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in HAM-D SubscaleCore Subscale Baseline47.6 score on a scaleStandard Deviation 6.96
PlaceboChange From Baseline in HAM-D SubscaleChange from Baseline in Core Subscale at Day 15-20.4 score on a scaleStandard Deviation 18.49
PlaceboChange From Baseline in HAM-D SubscaleAnxiety Subscale Baseline52.6 score on a scaleStandard Deviation 9.23
PlaceboChange From Baseline in HAM-D SubscaleChange from Baseline in Anxiety Subscale at Day 15-20.4 score on a scaleStandard Deviation 17.28
PlaceboChange From Baseline in HAM-D SubscaleBech-6-Subscale Baseline62.9 score on a scaleStandard Deviation 6.14
PlaceboChange From Baseline in HAM-D SubscaleChange from Baseline in Bech-6 Subscale at Day 15-24.6 score on a scaleStandard Deviation 21.37
PlaceboChange From Baseline in HAM-D SubscaleMeier Subscale Baseline56.3 score on a scaleStandard Deviation 5.94
PlaceboChange From Baseline in HAM-D SubscaleChange from Baseline in Meier Subscale at Day 15-22.5 score on a scaleStandard Deviation 18.99
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleChange from Baseline in Meier Subscale at Day 15-30.7 score on a scaleStandard Deviation 17.23
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleCore Subscale Baseline49.2 score on a scaleStandard Deviation 6.79
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleBech-6-Subscale Baseline63.7 score on a scaleStandard Deviation 5.64
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleChange from Baseline in Core Subscale at Day 15-27.7 score on a scaleStandard Deviation 16.36
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleMeier Subscale Baseline56.9 score on a scaleStandard Deviation 6.11
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleAnxiety Subscale Baseline51.2 score on a scaleStandard Deviation 8.79
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleChange from Baseline in Bech-6 Subscale at Day 15-34.3 score on a scaleStandard Deviation 19.61
SAGE-217 50 mgChange From Baseline in HAM-D SubscaleChange from Baseline in Anxiety Subscale at Day 15-26.0 score on a scaleStandard Deviation 15.66
Comparison: Change from Baseline in Core Subscale at Day 15p-value: 0.015195% CI: [-10.6, -1.2]MMRM
Comparison: Change from Baseline in Anxiety Subscale at Day 15p-value: 0.012395% CI: [-10.2, -1.3]MMRM
Comparison: Change from Baseline in Bech-6 Subscale at Day 15p-value: 0.00495% CI: [-14.5, -2.8]MMRM
Comparison: Change from Baseline in Meier Subscale at Day 15p-value: 0.004195% CI: [-12.7, -2.4]MMRM
Secondary

Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score

The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where \<17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement.

Time frame: Baseline and Day 15

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number of participants analyzed is the number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreBaseline24.7 score on a scaleStandard Deviation 5.96
PlaceboChange From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreChange from Baseline at Day 15-10.4 score on a scaleStandard Deviation 7.15
SAGE-217 50 mgChange From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreBaseline24.4 score on a scaleStandard Deviation 6.01
SAGE-217 50 mgChange From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreChange from Baseline at Day 15-13.0 score on a scaleStandard Deviation 8.19
Comparison: Change from Baseline at Day 15p-value: 0.023595% CI: [-4.2, -0.3]MMRM
Secondary

Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score

The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis.

Time frame: Baseline, Days 3, 8,15, 21, 28 and 45

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed are the number of participants with data available for analysis.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange form Baseline at Day 3-2.3 score on a scaleStandard Error 0.462
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 8-5.9 score on a scaleStandard Error 0.617
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 15-8.6 score on a scaleStandard Error 0.652
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 21-9.0 score on a scaleStandard Error 0.655
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 28-9.2 score on a scaleStandard Error 0.692
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 45-9.8 score on a scaleStandard Error 0.728
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 28-10.5 score on a scaleStandard Error 0.703
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange form Baseline at Day 3-2.0 score on a scaleStandard Error 0.456
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 21-10.6 score on a scaleStandard Error 0.651
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 8-7.7 score on a scaleStandard Error 0.62
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 45-11.7 score on a scaleStandard Error 0.731
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) ScoreChange from Baseline at Day 15-10.5 score on a scaleStandard Error 0.651
Comparison: Change from Baseline at Day 3p-value: 0.691295% CI: [-1, 1.5]MMRM
Comparison: Change from Baseline at Day 8p-value: 0.04195% CI: [-3.5, -0.1]MMRM
Comparison: Change from Baseline at Day 15p-value: 0.044495% CI: [-3.7, 0]MMRM
Comparison: Change from Baseline at Day 21p-value: 0.081195% CI: [-3.4, 0.2]MMRM
Comparison: Change from Baseline at Day 28p-value: 0.184695% CI: [-3.3, 0.6]MMRM
Comparison: Change from Baseline at Day 45p-value: 0.062595% CI: [-4, 0.1]MMRM
Secondary

Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score

The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement.

Time frame: Baseline, Days 3, 8,15, 21, 28 and 45

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 15-8.0 score on a scaleStandard Deviation 6.41
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 21-8.7 score on a scaleStandard Deviation 6.65
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreBaseline20.0 score on a scaleStandard Deviation 4.15
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 28-9.4 score on a scaleStandard Deviation 6.48
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 8-6.0 score on a scaleStandard Deviation 6.2
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 45-9.7 score on a scaleStandard Deviation 7.4
PlaceboChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 3-2.2 score on a scaleStandard Deviation 4.5
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 45-12.3 score on a scaleStandard Deviation 7.87
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreBaseline21.1 score on a scaleStandard Deviation 3.68
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 3-4.2 score on a scaleStandard Deviation 5.34
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 8-8.9 score on a scaleStandard Deviation 7.01
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 21-10.9 score on a scaleStandard Deviation 6.72
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 28-11.6 score on a scaleStandard Deviation 7.83
SAGE-217 50 mgChange From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total ScoreChange from Baseline at Day 15-10.8 score on a scaleStandard Deviation 7.18
Secondary

Change From Baseline in the 17-item HAM-D Total Score

The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis.

Time frame: Baseline, Days 3, 28 and 45

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analysis.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in the 17-item HAM-D Total ScoreBaseline28.8 score on a scaleStandard Deviation 2.34
PlaceboChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 3-6.3 score on a scaleStandard Deviation 6.78
PlaceboChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 28-13.5 score on a scaleStandard Deviation 8.77
PlaceboChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 45-14.8 score on a scaleStandard Deviation 9.09
SAGE-217 50 mgChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 45-17.7 score on a scaleStandard Deviation 8.4
SAGE-217 50 mgChange From Baseline in the 17-item HAM-D Total ScoreBaseline28.6 score on a scaleStandard Deviation 2.49
SAGE-217 50 mgChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 28-16.3 score on a scaleStandard Deviation 8.34
SAGE-217 50 mgChange From Baseline in the 17-item HAM-D Total ScoreChange from Baseline at Day 3-9.5 score on a scaleStandard Deviation 7.4
Comparison: Change from Baseline at Day 3p-value: 0.000895% CI: [-5.4, -1.4]MMRM
Comparison: Change from Baseline at Day 28p-value: 0.020395% CI: [-5.4, -0.5]MMRM
Comparison: Change from Baseline at Day 45p-value: 0.006795% CI: [-6, -1]MMRM
Secondary

Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement.

Time frame: Baseline and Day 15

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Overall number analyzed are the number of participants available for analysis. Number analyzed is the number of participants with data available for analyses.

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total ScoreBaseline35.0 score on a scaleStandard Deviation 4.81
PlaceboChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total ScoreChange from Baseline at Day 15-14.1 score on a scaleStandard Deviation 11.78
SAGE-217 50 mgChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total ScoreBaseline35.5 score on a scaleStandard Deviation 5.37
SAGE-217 50 mgChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total ScoreChange from Baseline at Day 15-19.9 score on a scaleStandard Deviation 12
Comparison: Change from Baseline at Day 15p-value: 0.003495% CI: [-8.4, -1.7]MMRM
Secondary

Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.

Time frame: Up to Day 45

Population: Safety Set included all participants who were administered IP.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)53.1 percentage of participants
SAGE-217 50 mgPercentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)66.3 percentage of participants
Secondary

Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response

The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of very much improved or much improved.

Time frame: Day 15

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Overall number analyzed is the number of participants available for analyses. Number analyzed is the number of participants with data available for analyses.

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response46.7 percentage of participants
SAGE-217 50 mgPercentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response66.7 percentage of participants
Comparison: Day 15p-value: 0.008995% CI: [1.223, 4.072]MMRM
Secondary

Percentage of Participants With HAM-D Remission

The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7.

Time frame: Days 15 and 45

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses. Percentages are rounded off to the nearest whole number.

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants With HAM-D RemissionDay 1516.7 percentage of participants
PlaceboPercentage of Participants With HAM-D RemissionDay 4529.4 percentage of participants
SAGE-217 50 mgPercentage of Participants With HAM-D RemissionDay 1526.9 percentage of participants
SAGE-217 50 mgPercentage of Participants With HAM-D RemissionDay 4544.0 percentage of participants
Comparison: Day 15p-value: 0.11195% CI: [0.876, 3.621]GEE Model
Comparison: Day 45p-value: 0.022695% CI: [1.108, 3.915]GEE Model
Secondary

Percentage of Participants With HAM-D Response

The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline.

Time frame: Days 15 and 45

Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants available for analyses. Percentages are rounded off to the nearest whole number.

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants With HAM-D ResponseDay 1538.9 percentage of participants
PlaceboPercentage of Participants With HAM-D ResponseDay 4554.1 percentage of participants
SAGE-217 50 mgPercentage of Participants With HAM-D ResponseDay 1557.0 percentage of participants
SAGE-217 50 mgPercentage of Participants With HAM-D ResponseDay 4561.9 percentage of participants
Comparison: Day 15p-value: 0.020995% CI: [1.112, 3.67]GEE Model
Comparison: Day 45p-value: 0.166195% CI: [0.837, 2.812]GEE Model

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026